english.prescrire.org > Spotlight > Archives : 2023 > Remdesivir (Veklury°) in covid-19 at increased risk of progression to severe disease, or in children on oxygen

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

2023 : 1 | 30 | 60

Remdesivir (Veklury°) in covid-19 at increased risk of progression to severe disease, or in children on oxygen

 Covid-19  In a double-blind randomised placebo-controlled trial in 562 unvaccinated patients with covid-19 (before the emergence of the Omicron variant of Sars-CoV-2) who did not require supplemental oxygen, a 3-day course of remdesivir reduced the proportion of patients hospitalised for acute care over the 28-day follow-up period. It is unclear whether these results can be transposed to the epidemiological context of 2023 in which a high proportion of the population has been immunised through vaccination or prior infection with Sars-CoV-2, and Omicron is by far the most dominant variant.
Full article available for download by subscribers

©Prescrire 1 November 2023

Source: "Remdesivir (Veklury°) in covid-19 at increased risk of progression to severe disease, or in children on oxygen" Prescrire Int 2023; 32 (253): 263-264. Subscribers only.

Enjoy full access to Prescrire International, and support independent information
Share
Share on Facebook Share on Twitter


See also:

"Molnupiravir and early
covid-19 without signs
of severe illness: value
uncertain, including
in unvaccinated patients
at risk of exacerbation"
Prescrire Int 2022;
 31 (235): 65-67.
Subscribers only

"Remdesivir - Veklury°.
Covid-19: too many
uncertainties over
its efficacy as well as
its harms"
Prescrire Int 2021;
 30 (222):14-15.
Subscribers only


Read more:

This month's contents

All the subjects in
Prescrire's Spotlight